BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)
Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
- DRUG: BI-754091 plus afatinib
Sponsor
National Health Research Institutes, Taiwan
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]